{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.00","value":"-0.7"},{"groupId":"OG001","spread":"5.36","value":"-1.1"}]}],"title":"Week 12 (n=40, 40)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.10","value":"0.7"},{"groupId":"OG001","spread":"5.03","value":"-1.0"}]}],"title":"Week 24 (n=26, 31)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.27","value":"-0.5"},{"groupId":"OG001","spread":"6.38","value":"-0.5"}]}],"title":"Week 36 (n=15, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.73","value":"0.4"},{"groupId":"OG001","spread":"5.47","value":"-1.9"}]}],"title":"End of Treatment (n=23, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Right ventricular function was assessed by measuring fractional area change (FAC) on echocardiogram.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received bortezomib 1.3 mg/m² administered intravenously (IV) or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone (DEX) 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.","id":"OG000","title":"Bortezomib + DEX"},{"description":"Participants received 20 mg/m² carfilzomib administered by IV infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.","id":"OG001","title":"Carfilzomib + DEX"}],"paramType":"MEAN","populationDescription":"Cardiopulmonary Safety Evaluable subgroup with available FAC data at baseline; \"n\" indicates participants whose results were available at both the baseline and the specified post-baseline visit.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 12, 24 and 36 and at end of treatment (median duration of treatment was 27 weeks in the bortezomib group and 40 weeks in the carfilzomib treatment group).","title":"Change From Baseline in Right Ventricular Fractional Area Change (FAC)","type":"SECONDARY","unitOfMeasure":"percent fractional area change"}